key: cord-1033665-baitnfoc authors: Leslie-Mazwi, Thabele M; Srivatanakul, Kittipong title: Coronavirus disease 2019 and stroke date: 2021-10-20 journal: Interv Neuroradiol DOI: 10.1177/15910199211035920 sha: 695f37a351c8915810cc46b6cf1093c56f1f5944 doc_id: 1033665 cord_uid: baitnfoc The multisystem nature of coronavirus disease 2019 has become increasingly clear over the course of the pandemic. Both the neurological and vascular systems are affected, impacting acute stroke. This impact can be conceptualised as direct and indirect effects of the disease. The direct effects of coronavirus disease 2019 on stroke are thought to relate to receptor-mediated tissue invasion and the marked inflammatory response to the presence of the virus. These effects include coagulopathies, endotheliitis, systemic inflammation and atherosclerotic plaque instability, with possibly long-term cardiovascular effects. The indirect effects impact all aspects of stroke care delivery. These extend far beyond the direct effects of coronavirus disease 2019, and represent an essential focus for stroke systems of care. In this article, we detail the impact of coronavirus disease 2019 on acute stroke. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces the illness coronavirus disease 2019 (COVID-19). 1 After reaching pandemic proportions in March 2020, 2 it has become increasingly clear that the disease will continue to affect the human population in many ways in the months and years to come. Though predominantly respiratory, increasingly the infection is appreciated as a multisystem disease. Both neurologic and vascular involvement has been reported, and appropriately concern has been high that the disease has an impact on acute stroke. This impact is both direct and indirect. Multiple mechanisms are likely to be at play in the direct impact of COVID-19 on stroke, but are only partially understood. It is now apparent that the angiotensin-converting enzyme 2 receptor is the functional receptor allowing coronavirus to infect humans. 3 This membrane-bound aminopeptidase plays both a vascular and immunological role, and is highly expressed in cardiac, vascular and pulmonary tissue. This receptor-mediated initial tissue invasion, and then the marked inflammatory response to the presence of the virus, are thought to produce several of the direct effects of COVID-19 on stroke. 4 As a result of these direct effects, stroke is seen in patients with limited vascular risk factors otherwise, and in age groups that are unusual for ischemic stroke. 5, 6 While there is strong pathophysiological plausibility to this, caution is required in interpreting this risk. Reports of similar findings of stroke in unusual populations are not widespread in other epicentres in China, Europe, and much of the most affected regions in the United States, 7 surprising given the incidence reported in published positive samples. Publication bias and sample limitations likely play a prominent role. 8 Despite this caution, though, it seems likely that stroke presentations are directly impacted by the virus. A clinical phenotype characterised by older age, a higher burden of comorbidities and severe COVID-19 respiratory symptoms, appears to be associated with the highest in-hospital mortality after stroke (almost 60%), and large-vessel occlusions (LVOs) are seen twice as frequently as in the non-COVID-19 population. 9 In a 1527 patient sample from China a combined datapoint of cardiac or cerebrovascular disease was found in 16.4% of the total cohort. 10 Available data suggests a risk of acute cerebrovascular events alone of between 1.3% and ∼5% in patients with confirmed COVID-19 infection. 11, 12 This includes both documented haemorrhagic and ischemic strokes. Further, these imaging findings are associated with markers of disease severity (the requirement for intensive care admission, intubation and acute kidney injury) that suggest that patients with more severe forms of COVID-19 may be more prone to the direct impact of the disease on their stroke risk, 13 perhaps by as much as a factor of three. 10 Several interacting mechanisms are at play. 14 A severe coagulopathy is recognised in patients with severe COVID-19. The characteristics of this coagulopathy (are distinct from those seen with sepsis or disseminated intravascular coagulation are marked by elevated D-dimer and fibrinogen levels but minimal initial abnormalities in prothrombin time or platelet count. 15 Antiphospholipid antibodies have been described, and may further contribute to thrombotic tendencies. 16 This coagulopathy and prothrombotic tendency raise concern for both venous and arterial side thromboses, and subsequent strokes. Arterial ischemia in these patients can be macrovascular, in the form of LVOs, or microvascular. The possibility of increased LVO stroke has been reported in case series. In a New York City 329 patient cohort, LVO was present in 31.7% of patients with COVID-19 compared with 15.3% of patients without COVID-19 (P = 0.001), while small vessel occlusions were comparable. 17 A total of 27% of LVO presentations to a Paris hospital during the pandemic peak were COVID-19 positive, with limited respiratory symptoms in the patients affected. Impressively, half of patients had LVO in multiple territories simultaneously. 18 Clot in these patients appears abnormally friable with a reported increased propensity for clot fragmentation during thrombectomy procedures. 19 tPA is safe for these patients, with possibly even a lower risk of haemorrhagic conversion (consistent with a procoagulant state). 20 In addition, venous prothrombotic tendencies have been identified as catastrophic cerebral venous thrombosis in young, previously healthy patients with limited precipitating factors. 21 Haemorrhagic cerebrovascular disease is less common, ∼0.2% of COVID-19 in a recent cohort, 22 and less well defined. Deranged coagulation parameters, and markedly elevated D-dimer levels are common findings, and microcirculatory dysfunction appears to contribute further, with a common pattern of multifocal subcortical/cortical petechial-type hemorrhages. 23 These manifestations are more frequently seen in patients that are severely affected in other organ systems by COVID-19. 24 While reports of aneurysmal subarachnoid haemorrhage also exist it remains impossible with the limited case numbers to determine if concomitant COVID-19 infection led to instability of the aneurysm wall and subsequent rupture. 25 This challenge holds for all forms of COVID-19 related haemorrhage and stroke in general: making the distinction between characterisation and causation. 22, 26 Endotheliitis Pathological specimens in COVID-19 patients reveal the presence of viral elements within endothelial cells, with inflammatory cell infiltration. Associated with this is evidence of endothelial and inflammatory cell death. This induction of endotheliitis, identified in several organs, is presumably as a direct consequence of viral involvement. 27 In the cerebral vasculature the subsequent impaired endothelial function may lead to detrimental shifts in the vascular equilibrium towards vasoconstriction or a pro-coagulant state resulting in thrombosis (manifesting clinically as brain ischemia and infarction). 28 Inflammatory cytokines and vasoactive molecules enhance endothelial cell contractility and the loosening of inter-endothelial junctions, predisposing to leakage through the blood-brain barrier, with haemorrhagic changes. 29 This proposed central role of endothelial cells raises the question of whether vascular normalisation strategies may modify disease features, possibly including stroke risk. Systemic inflammation secondary to viral infection has been described to increase vascular events and mortality, predominantly for cardiac disease. 30 Mechanisms in the context of chronic atherosclerotic vascular disease are largely felt to relate to impact on plaque morphology from inflammation, biomechanical stress and vasoconstriction. 31 Inflammation alone can lead to thinning of the fibrous cap, lipid influx and expansion of the lipid core, all factors that destabilise the plaque. 32 While details are limited in the COVID-19 population for cerebral ischemic disease there are isolated reports of higher than expected carotid plaque instability, associated with acute stroke. 33 Importantly, this may happen in patients less severely affected than many COVID-19 patients that are critically ill when they manifest acute stroke symptomatology. Collateral circulation maintains tissue viability in the event of acute ischemic stroke, and therefore limits final infarct size. This vulnerable penumbral tissue is subject to fluctuations in blood oxygen and blood pressure. Both these issues are frequent in COVID-19. Hypoxemia can be profound, requiring proning in severe cases, and in COVID-19 is independently associated with in-hospital mortality. 34 Coronavirus infection further results in monocyte, macrophage, and dendritic cell activation, and widespread IL-6 release that instigates an amplification cascade with increased signalling in many cell types, such as endothelial cells as discussed above. The resulting increased systemic cytokine production contributes to the pathophysiology of severe COVID-19, including hypotension, cardiac arrhythmias and reduced cardiovascular reserve. This systemic milieu is detrimental to the sustenance of tenuous penumbral tissue and may serve to further amplify the impact of acute stroke in this population. Metabolic syndrome is a cluster of metabolic disorders that can lead to serious health conditions. Established features include three or more of the following: visceral adiposity, insulin resistance, glucose intolerance, endothelial dysfunction, hypertension and dyslipidaemia. Coronaviruses (and other viruses) metabolically engineer host cells by manipulating gene expression and lipid metabolism to allow enhanced viral replication and progeny release while simultaneously evading host immune responses. Viral infection therefore further potentiates metabolic disease severity. 35 The phenotype of metabolic syndrome is shared by many patients at risk for stroke, which may increase the likelihood of severe disease in this population. Optimal control of these vascular risk factors is imperative for patients infected with or at risk for COVID-19. 36 Further, the longer-term implications of infection in patients at risk for metabolic syndrome are unknown. After the severe acute respiratory syndrome outbreak survivors demonstrated altered lipid metabolism over a decade later. 37 Whether similar long-term concerns will exist for the recovered SARS-CoV-2 population is unknown, but if so may have direct implications for future acute stroke risk and vascular health in general. While much remains unknown about the direct impact of COVID-19 on stroke, and the proportion of patients affected, the indirect impact is more clear. 38 There are several challenges for stroke patients during the pandemic. Mandated social distancing and self-isolation may delay discovery of affected patients. For patients with identified symptoms concerns about COVID-19 exposure in the healthcare environment may limit willingness to present for care. During pandemic peaks or surges there may be a significant strain on ambulance transport, and the required precautions taken by all healthcare providers at all points in the stroke chain of care will lead to requisite delays. 39 These multiple effects may decrease access to treatment for affected patients. Given the immense therapeutic benefit of acute stroke therapies, and the burden of stroke in our communities at large, it remains an imperative for health care systems to ensure that access is maintained for these essential services, despite the range of indirect effects of COVID-19 on stroke. 40 A variety of indirect effects are recognised. Public awareness of stroke has long been a challenge in the management of acute stroke. The majority of patients potentially eligible for acute therapies are ineligible because of late presentation to care. In addition, historically patients with more mild deficits are slow to seek medical attention. 41 In the context of the COVID-19 pandemic these observations have remained true. In Hong Kong, for example, the median symptom onset-to-door time was up to 60 min longer, fewer patients with transient ischemic attacks sought hospital treatment, and the proportion of patients arriving within the therapeutic time window of IV r-tPA was significantly lower. 42 Patients with mild deficits, already slow to seek attention, are even less likely to do so when faced with the concern of COVID-19 exposure in the healthcare environment. Studies have reported a decrease in more mild stroke presentations. 43 This decrease occurred in regions with low COVID-19 incidence, suggesting that patient concerns about contracting COVID-19 in hospitals was a primary driver, rather than actual hospital congestion. 44 Emergency services during the pandemic experienced an overall emergency medical services (EMS) activation decrease, but on-scene deaths and on scene time increases. 45 The impact of this on available emergent transport to collect patients from their homes or move them between facilities remains to be clarified. Compounding this is the high routine potential exposure risk to EMS providers. This requires a variety of adaptations in the field when assessing an acute stroke patient, 46 including the use of personal protective equipment, and sending a 'scout' into the dwelling to assess the potential for COVID-19 in the home. These requirements add time delay and may limit the effectiveness of the initial evaluation of the patient, not just in assessing disease severity but in obtaining details such as last seen well and family contact information. Finally, patient triage to a centre capable of delivering thrombectomy may undergo reorganisation in systems that take a global approach to their care delivery, requiring frequent EMS adaptation and re-education. In regions experiencing pandemic surges, there is the distinct possibility of centres that provide thrombectomy level services becoming overwhelmed for capacity due to the intensive care unit (ICU) needs of the severely affected COVID-19 population at large. This limits the availability of these institutions for the care of acute stroke patients that require thrombectomy. In models borrowed from cardiology, 47 a care system can establish designated thrombectomy sites for patients presenting with evidence of a secure neurologic deficit in the field. 48 These locations would ensure access to ICU beds, angiography suites, the relevant personnel and equipment for patients with neurologic deficits who may require thrombectomy. Alternatively, hospital administration must commit to ensuring access for this vulnerable population. 40 Further consideration is the sequential effect of the required precautions that COVID-19 adds to the evaluation of stroke patients. These patients present almost invariably with unknown COVID-19 status and often fragmentary history. Given that acute stroke may be a presenting symptom of COVID-19 precautions are required for all personnel. This process, termed Protected Code Stroke, 49 adds a significant delay. This delay is further exacerbated for interfacility transfers. Data from France showed a significant increase in delays between imaging and groin puncture, overall (mean 144.9 min in 2020 vs 126.2 in 2019; P < 0.001) and in transferred patients (mean 182.6 min vs 153.25; P < 0.001). 19 A recent meta-analysis showed that the number of stroke alerts during the pandemic was 64% of that during the pre-pandemic period, while the number of reperfusion therapies during the pandemic dropped to 69% of that during the pre-pandemic period. 50 These delays and decreases translate into patient disability. Further delays due to modifications to inpatient processing must be the focus of specific mitigation strategies, as outlined in several societal and regional publications. 40, [51] [52] [53] [54] Acute stroke team health COVID-19 can have a significant impact on the acute stroke care team. This can be direct in the form of infections within care personal. In centres with limited neuroendovascular specialists, radiology technologists or interventional nurses the loss of a few key members of the team may severely hamper the ability to deliver care. Fortunately available data for the United States suggests that infection rates among providers were low. 55 This is a testament to effective precautionary measures and an indication that they should continue until better control of the disease globally is achieved. More insidious is the emotional and psychological toll of the disease as teams worry about their personal health, the health of their families and the future of their practice. 56 This toll may affect the ability of teams to effectively care for the acute stroke patient. Finally, COVID-19 has had a direct impact on the ability of the field to study stroke. Recent data have indicated widespread trial disruption. Following COVID-19, enrolment was suspended at 78% of surveyed sites at which advanced trial infrastructure existed. Beyond this, trial quality was compromised with patients missing clinical and imaging follow-up, and many sites reporting pandemic-related protocol deviations. Human trial expertise has also been affected by the COVID-19 pandemic, with reassignment, furloughing or termination of study coordinators. 57 What the long-term impact is of this on the science and pace of progress in acute stroke remains to be seen. COVID-19 has produced healthcare consequences unprecedented in our lifetimes. Stroke, as with other diseases, is affected in both direct and indirect ways. While understanding the direct impact is vital for disease modification and effective treatment of the individual patient, understanding the indirect effects will allow an effective systemic response. 8 Strong systems of stroke care will enable us to withstand this pandemic and those likely to follow. 58 The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Coronavirus disease (COVID-19) pandemic 2020 ACE2: from vasopeptidase to SARS virus receptor The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Large-vessel stroke as a presenting feature of COVID-19 in the young Characteristics of largevessel occlusion associated with COVID-19 and ischemic stroke SARS-CoV-2 and stroke in a New York healthcare system The forest and the trees Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study Risk of acute cerebrovascular events in patients with COVID-19 infection Clinical and neuroimaging correlation in patients with COVID-19 Mechanisms of stroke in COVID-19 The unique characteristics of COVID-19 coagulopathy Coagulopathy and antiphospholipid antibodies in patients with COVID-19 Association of coronavirus disease (COVID-19) with large vessel occlusion strokes: a case-control study Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: decreased activity, and increased care delays Intravenous tPA for acute ischemic stroke in patients with COVID-19 Cerebral venous thrombosis associated with COVID-19 COVID-19 and stroke: incidence and etiological description in a highvolume center Neuroimaging findings in patients with COVID-19 Cerebral microbleeds and leukoencephalopathy in critically Ill patients with COVID-19 Neuroradiologic manifestations of COVID-19: what the emergency radiologist needs to know The critical distinction between characterisation and causation in studies of COVID-19-associated cerebrovascular pathology Endothelial cell infection and endotheliitis in COVID-19 Endotheliitis and endothelial dysfunction in patients with COVID-19: its role in thrombosis and adverse outcomes COVID-19: the vasculature unleashed Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects Acute myocardial infarction after laboratory-confirmed influenza infection Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging Intraluminal carotid artery thrombus in COVID-19: another danger of cytokine storm? Association between hypoxemia and mortality in patients with COVID-19 Metabolic syndrome and viral pathogenesis: lessons from influenza and coronaviruses Endocrine and metabolic link to coronavirus infection Altered lipid metabolism in recovered SARS patients twelve years after infection Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry Break in the stroke chain of survival due to COVID-19 Preserving access: a review of stroke thrombectomy during the COVID-19 pandemic Out-of-hospital delays in patients with acute stroke Delays in stroke onset to hospital arrival time during COVID-19 Acute stroke presentation, care, and outcomes in community hospitals in northern California during the COVID-19 pandemic Where have our patients gone? The impact of COVID-19 on stroke imaging and intervention at an Australian stroke center Effect of the coronavirus disease 2019 (COVID-19) pandemic on the U.S. Emergency medical services system: a preliminary report European society for emergency medicine position paper on emergency medical systems' response to COVID-19 Critical organizational issues for cardiologists in the COVID-19 outbreak Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak Protected code stroke: hyperacute stroke management during the coronavirus disease 2019 (COVID-19) pandemic Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression Temporary emergency guidance to US stroke centers during the COVID-19 pandemic Society of neurointerventional surgery recommendations for the care of emergent neurointerventional patients in the setting of COVID-19 Neurointervention for emergent large vessel occlusion during the COVID-19 pandemic Acute stroke care is at risk in the era of COVID-19: experience at a comprehensive stroke center in Barcelona The professional and personal impact of the coronavirus pandemic on US neurointerventional practices: a nationwide survey Managing mental health challenges faced by healthcare workers during COVID-19 pandemic Neuroendovascular clinical trials disruptions due to COVID-19. Potential future challenges and opportunities Innovation for pandemics The authors received no financial support for the research, authorship and/or publication of this article.